Sionna Therapeutics, Inc. (SION)

Sionna Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	35.75	38.52	54.84
Short-Term Investments	101.73	-	27.77
Cash & Cash Equivalents	137.47	38.52	82.61
Cash Growth	-	-53.37%	-
Other Current Assets	2.86	0.69	1.22
Total Current Assets	140.34	39.21	83.83
Property, Plant & Equipment	-	3.11	2.57
Goodwill and Intangibles	-	8.63	-
Other Long-Term Assets	-	1.01	0.96
Total Long-Term Assets	-	12.74	3.54
Total Assets	-	51.95	87.37
Accounts Payable	-	0.72	0.56
Current Debt	-	0.73	-
Other Current Liabilities	6.48	6.59	7.7
Total Current Liabilities	6.48	8.04	8.25
Long-Term Debt	-	9.75	-
Total Long-Term Liabilities	-	9.75	0
Total Liabilities	-	17.79	8.25
Total Debt	10	10.48	0
Retained Earnings	-	-119.4	-72.14
Comprehensive Income	-	-	-0.02
Shareholders' Equity	-148.55	-114.88	-69.92
Net Cash / Debt	127.48	28.04	82.61
Net Cash / Debt Growth	-	-66.05%	-
Working Capital	133.86	31.17	75.58

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).